Axovant Sciences (NASDAQ:AXON) shares hit a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $1.11 and last traded at $1.13, with a volume of 284498 shares. The stock had previously closed at $1.15.
Several analysts recently weighed in on the stock. ValuEngine upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Wednesday, January 31st. Cowen reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Finally, Chardan Capital upgraded shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 price target on the stock in a report on Wednesday, January 10th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $13.61.
The firm has a market cap of $127.19, a price-to-earnings ratio of -0.62 and a beta of -0.40. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.58 and a current ratio of 4.58.
Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC purchased a new position in Axovant Sciences during the third quarter valued at $117,000. Wells Fargo & Company MN lifted its position in Axovant Sciences by 135.6% during the third quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 30,905 shares during the period. Virtus Fund Advisers LLC purchased a new position in Axovant Sciences during the fourth quarter valued at $349,000. Hikari Power Ltd purchased a new position in Axovant Sciences during the fourth quarter valued at $377,000. Finally, Alliancebernstein L.P. lifted its position in Axovant Sciences by 108.8% during the fourth quarter. Alliancebernstein L.P. now owns 108,600 shares of the biotechnology company’s stock valued at $572,000 after buying an additional 56,600 shares during the period. 93.03% of the stock is owned by institutional investors and hedge funds.
About Axovant Sciences
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.